At a glance
The mechanistic ageing paper primarily concerns cells and mice, including an intervention that raises NAD+ through a precursor. A small direct-infusion human study measured metabolic handling, not longevity, energy benefits or disease treatment.
Identity & scope
Nicotinamide adenine dinucleotide in its oxidised form, NAD+, participates in redox and other cellular reactions. Compounds such as NMN and NR are precursors, not interchangeable names for NAD+.
What the research shows
- Gomes and colleagues connected declining nuclear NAD+ with disrupted mitochondrial communication in experimental ageing models.
- Grant and colleagues tracked plasma and urinary metabolites during and after direct NAD+ infusion, showing substantial metabolic handling before a sustained plasma increase.
Critical interpretation
Concentration, flux and clinical benefit are different endpoints
NAD+ research often moves between circulating concentrations, intracellular pools and enzyme activity. A change in one compartment cannot automatically establish a change in another. The infusion pilot is useful for identifying metabolic handling and future sampling questions, but its design does not supply a counterfactual for improved cognition or ageing. Those outcomes would need their own adequately controlled measurements rather than being inferred from a metabolite curve. [2] [1]
The precursor contrast is informative, not interchangeable
The NMN trial gives an example of a specific human physiological endpoint changing while several broader outcomes do not. Our interpretation is that a positive mechanistic or metabolic signal should stay attached to the actual compound and endpoint. It is not evidence that an equal labelled quantity of NAD+ produces the same exposure or effect. A literature review should therefore extract intervention identity and route before grouping studies under a common NAD biology heading. [3]
A useful next experiment
The unresolved bridge is reproducible exposure to direct NAD+ together with a prespecified functional outcome. Suitable controls, validated handling of unstable metabolites and tissue-relevant measurements would help distinguish target engagement from a clinically useful effect. Longer lifespan is a separate hypothesis, not a synonym for either. [1] [2] [3]
Limitations & uncertainties
- A precursor intervention cannot directly establish the effect of an NAD+ vial or spray.
- Changes in metabolite concentrations do not establish a meaningful health outcome.
- The small infusion pilot does not resolve long-term safety or validate a catalogue formulation.
Open research questions
- Do sufficiently controlled human trials show durable functional outcomes from direct NAD+ itself?
- Which analytical measures establish tissue exposure rather than only a change in circulating metabolites?
Selected papers & source records
Download bibliography1. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging (opens in a new tab)
Gomes AP, Price NL, Ling AJY, et al. (2013). Cell. DOI: 10.1016/j.cell.2013.11.037 (opens in a new tab) · PMID 24360282
- Design & population
- Cell and mouse experiments investigating SIRT1, NAD+ and nuclear-mitochondrial signalling during ageing.
- What the study found
- Linked declining NAD+ to altered mitochondrial gene expression and reported reversal of selected mitochondrial changes when NAD+ was raised in old mice.
- Limits on interpretation
- Mechanistic and precursor-related evidence, not a trial of a direct NAD+ catalogue product.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
2. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ (opens in a new tab)
Grant R, Berg J, Mestayer R, et al. (2019). Frontiers in Aging Neuroscience. DOI: 10.3389/fnagi.2019.00257 (opens in a new tab) · PMID 31572171
- Design & population
- Small human metabolic pilot with eleven men, eight receiving NAD+ and three saline controls.
- What the study found
- Measured time-dependent plasma and urinary NAD+ metabolites; plasma NAD+ did not rise during the first two hours.
- Limits on interpretation
- Very small, short metabolic study without a clinical efficacy endpoint. It cannot substantiate anti-ageing or cognitive benefit.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
3. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (opens in a new tab)
Yoshino M, Yoshino J, Kayser BD, et al. (2021). Science. DOI: 10.1126/science.abe9985 (opens in a new tab) · PMID 33888596
- Design & population
- Ten-week double-blind placebo-controlled NMN study in 25 postmenopausal women with prediabetes who were overweight or obese, using metabolic clamps and muscle biopsies.
- What the study found
- Reported increased muscle insulin sensitivity and signalling, without corresponding changes in several body-composition, physical-function or other metabolic measures.
- Limits on interpretation
- This is an NMN precursor study in a selected population, not direct NAD+ treatment or a longevity trial.
Original source (opens in a new tab) · Full text at publisher / archive (opens in a new tab)
Search & review scope
Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.. Checked 9 November 2026.
Mechanistic NAD+ biology, a small direct-infusion metabolic pilot and a human NMN precursor contrast. Selected full-text sections consulted; the NMN source was also intermittently blocked on direct retrieval.
Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates.
Recorded search terms
- site:pubmed.ncbi.nlm.nih.gov NAD+ intravenous infusion pilot study plasma urine metabolome 2019 Grant
- "31572171" "10." Grant
- "A Pilot Study Investigating Changes" "Grant" 2019 NAD metabolome
- nicotinamide mononucleotide muscle insulin sensitivity prediabetic women randomized 2021 Yoshino PubMed
- "10.1016/j.cell.2013.11.037" correction retraction
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. NAD+: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/us/research/library/nad-plus.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.